Treating Depression with Esketamine
Depression can impact every facet of life and drain the joy out of even the simplest moments.
For those struggling with Treatment-Resistant Depression, the battle can become even tougher, as conventional treatments can fall short in providing much-needed relief.
SPRAVATO® (esketamine) is an FDA-approved nasal spray designed specifically for individuals grappling with Treatment-Resistant Depression and can offer renewed possibilities for hope and recovery.
HOW DOES SPRAVATO® (ESKETAMINE) WORK?
In depression, certain areas of the brain may be underactive, leading to symptoms such as low mood, loss of interest, and feelings of hopelessness.
Esketamine helps to restore balance by promoting the formation of new connections between brain cells, known as synapses, in these underactive areas. This process enhances learning functions and eventually trains the brain to adapt to a more comfortable and positive state.
WHAT TO EXPECT DURING ESKETAMINE TREATMENT
SPRAVATO® (esketamine) is self-administered via nasal spray by the patient under supervision of a health care provider at the clinic. Patients then rest for the next two hours in a relaxation lounge. The attending health care provider checks in with them during that period, while a nurse monitors their vital signs and addresses any temporary adverse effects, such as a rise in blood pressure or feelings of sedation.
During Weeks 1-4, clients come to the clinic twice a week.
During Weeks 5-9, clients come to the clinic once a week.
After Week 9, a consultation with the doctor will take place to determine the further course of treatment.
SPRAVATO® (esketamine) is covered by most insurance plans. If insurance coverage isn’t an option, we can also work with you to develop an out-of-pocket payment plan to cover the cost of treatment.
IS SPRAVATO® (ESKETAMINE) RIGHT FOR ME?
Like Transcranial Magnetic Stimulation (TMS), which ServiceNet also offers at its Northampton clinic, esketamine is available for those with Treatment-Resistant Depression who have met the medical criteria as determined by the psychiatrist and the insurance provider.
Esketamine patients must also qualify through a Risk Evaluation and Mitigation Strategy (REMS) Program to ensure that the use of the drug is an appropriate treatment option for them.